Literature DB >> 23323858

HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage.

Ji-hyun Ju1, Wonseok Yang, Sunhwa Oh, KeeSoo Nam, Kyung-min Lee, Dong-young Noh, Incheol Shin.   

Abstract

In breast cancer, the HER2 (human epidermal growth factor receptor 2) receptor tyrosine kinase is associated with extremely poor prognosis and survival. Notch signalling has a key role in cell-fate decisions, especially in cancer-initiating cells. The Notch intracellular domain produced by Notch cleavage is translocated to the nucleus where it activates transcription of target genes. To determine the combinatory effect of HER2 and Notch signalling in breast cancer, we investigated the effect of HER2 on Notch-induced cellular phenomena. We found the down-regulation of Notch-dependent transcriptional activity by HER2 overexpression. Also, the HER2/ERK (extracellular-signal-regulated kinase) signal pathway down-regulated the activity of γ-secretase. When we examined the protein level of Notch target genes in HER2-overexpressing cells, we observed that the level of survivin, downstream of Notch, increased in HER2 cells. We found that activation of ERK resulted in a decrease in XAF1 [XIAP (X-linked inhibitor of apoptosis)-associated factor 1] which reduced the formation of the XIAP-XAF1 E3 ligase complex to ubiquitinate survivin. In addition, Thr(34) of survivin was shown to be the most important residue in determining survivin stability upon phosphorylation after HER2/Akt/CDK1 (cyclin-dependent kinase 1)-cyclin B1 signalling. The results of the present study show the combinatorial effects of HER2 and Notch during breast oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23323858     DOI: 10.1042/BJ20121716

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  16 in total

1.  Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.

Authors:  Francesca De Iuliis; Gerardo Salerno; Anna Giuffrida; Bernardina Milana; Ludovica Taglieri; Giovanna Rubinacci; Sabrina Giantulli; Federica Terella; Ida Silvestri; Susanna Scarpa
Journal:  Tumour Biol       Date:  2015-09-21

Review 2.  The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Authors:  Elisabeth J Diver; Rosemary Foster; Bo R Rueda; Whitfield B Growdon
Journal:  Oncologist       Date:  2015-06-22

Review 3.  The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.

Authors:  A Dittrich; H Gautrey; D Browell; A Tyson-Capper
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-12-28       Impact factor: 2.673

Review 4.  Notch signaling in breast cancer: From pathway analysis to therapy.

Authors:  B Madhu Krishna; Samir Jana; Jyotsana Singhal; David Horne; Sanjay Awasthi; Ravi Salgia; Sharad S Singhal
Journal:  Cancer Lett       Date:  2019-07-18       Impact factor: 8.679

Review 5.  Survivin - biology and potential as a therapeutic target in oncology.

Authors:  Chun Hei Antonio Cheung; Chien-Chang Huang; Fang-Ying Tsai; Jane Ying-Chieh Lee; Siao Muk Cheng; Yung-Chieh Chang; Yi-Chun Huang; Shang-Hung Chen; Jang-Yang Chang
Journal:  Onco Targets Ther       Date:  2013-10-16       Impact factor: 4.147

6.  Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance.

Authors:  P Dahan; J Martinez Gala; C Delmas; S Monferran; L Malric; D Zentkowski; V Lubrano; C Toulas; E Cohen-Jonathan Moyal; A Lemarie
Journal:  Cell Death Dis       Date:  2014-11-27       Impact factor: 8.469

Review 7.  Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer.

Authors:  Andrew T Baker; Andrei Zlobin; Clodia Osipo
Journal:  Front Oncol       Date:  2014-12-12       Impact factor: 6.244

8.  Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.

Authors:  Danielle D Jandial; Lauren S Krill; Lixia Chen; Chunli Wu; Yu Ke; Jun Xie; Bang H Hoang; Xiaolin Zi
Journal:  Molecules       Date:  2017-03-14       Impact factor: 4.411

Review 9.  Notch Signalling in Breast Development and Cancer.

Authors:  Abigail Edwards; Keith Brennan
Journal:  Front Cell Dev Biol       Date:  2021-07-06

Review 10.  Survivin as a preferential target for cancer therapy.

Authors:  Mahsa Mobahat; Aru Narendran; Karl Riabowol
Journal:  Int J Mol Sci       Date:  2014-02-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.